Wegovy lists at $1,349/month — the highest sticker price of any major GLP-1. Almost no patient actually pays that. The seven legitimate cheaper paths in June 2026: $25/mo via Wegovy Savings Card (insured + Wegovy coverage), $50/mo via Medicare bridge (starts July 1, 24 days away), $25/mo via Ozempic Savings Card (if you have Type 2 diabetes), $249/mo via NovoCare cash-pay direct, $99-$249/mo via compounded semaglutide, $149/mo via oral Foundayo (orforglipron), or $1,349/mo retail. The path that fits depends on three things: whether you have commercial insurance, whether your insurance plan covers Wegovy specifically, and whether you have a Type 2 diabetes diagnosis. Below: the full breakdown, the timing decision around July 1, and the commission-first compounded provider list if cash-pay is your route.
The 7 paths to cheaper Wegovy (June 2026)
| Path | Monthly cost | Eligibility | Speed | |---|---|---|---| | Wegovy Savings Card | $25/mo (12 fills) | Commercial insurance with Wegovy on formulary | 1-7 days | | Medicare Bridge | $50/mo flat | Part D, BMI ≥30 (or ≥27 + comorbidity), starts July 1, 2026 | After July 1 | | Ozempic Savings Card | $25/mo | Commercial insurance + Type 2 diabetes diagnosis | 1-7 days | | NovoCare cash-pay | $249/mo | None — direct from Novo Nordisk | 3-7 days | | Compounded semaglutide | $99-$249/mo | None — cash-pay only | Same week | | Oral Foundayo (orforglipron) | $149/mo | Telehealth prescription | 5-7 days | | Brand Wegovy retail | $1,349/mo | None — full self-pay or no insurance | Standard |
The pure-cash buyer's cheapest legitimate path is compounded semaglutide at $99/month via Embody — same active molecule (semaglutide) at 1/14th the retail price. The insured buyer's cheapest path is the Wegovy Savings Card at $25/month if your plan covers Wegovy, or the Ozempic Savings Card at $25/month if you have a Type 2 diabetes diagnosis. The Medicare buyer 60+ should wait 24 days for the $50/month bridge starting July 1, 2026.
Path 1: Wegovy Savings Card — $25/month if your plan covers Wegovy
Novo Nordisk's Wegovy Savings Card is the cheapest legitimate path for patients with commercial insurance whose plan has Wegovy on formulary.
What it costs: $25/month copay for up to 12 fills per year. After 12 fills the card resets if your plan still covers Wegovy in the next benefit year.
Who qualifies: - Commercial insurance (employer plan, marketplace plan) - Wegovy is on your plan's formulary - BMI ≥30 OR BMI ≥27 with weight-related condition - US resident, age 18+ - NOT eligible: Medicare, Medicaid, TRICARE, or any government-funded insurance
How to enroll: Get a Wegovy prescription, then download the savings card at wegovy.com/savings-card. Show it at the pharmacy at fill.
The catch: Far fewer commercial plans cover Wegovy than Ozempic. In 2024-2025 many large employers dropped GLP-1 coverage for obesity (versus T2D). Check your plan's formulary before assuming this path is open. If Wegovy is excluded, jump to the Ozempic savings card or compounded path.
Path 2: Medicare Bridge — $50/month starting July 1, 2026
The federal $50/month GLP-1 bridge program launches July 1, 2026. It's the cheapest legitimate option for Medicare Part D patients who qualify.
What it costs: $50/month flat for brand Wegovy.
Who qualifies: - Medicare Part D enrollee - BMI ≥30 OR BMI ≥27 with weight-related comorbidity (T2D, hypertension, sleep apnea, dyslipidemia, cardiovascular disease) - Prescription from any Medicare-credentialed prescriber - Documented BMI in your Medicare record
Who doesn't qualify: - Medicare Advantage plans without Part D - Medicaid-only enrollees (separate state-by-state programs) - Commercial insurance enrollees (use the Wegovy Savings Card path instead)
The timing decision: You're reading this 24 days from launch. If you qualify, wait. If you don't qualify but think you might (BMI borderline, no documented comorbidity yet), schedule a Medicare-credentialed primary care visit this week to get the BMI and comorbidities documented in your chart before July 1. The bridge is a verifiable Medicare benefit — your prescriber needs documentation, not new bloodwork.
Path 3: Ozempic Savings Card — $25/month (if you have T2D)
If you have a Type 2 diabetes diagnosis AND commercial insurance covering Ozempic, the Ozempic Savings Card gets you semaglutide at $25/month. Ozempic is the same active molecule as Wegovy — semaglutide — at slightly lower doses (max 2.0mg/week vs Wegovy's 2.4mg/week).
What it costs: $25/month copay for up to 24 months.
Who qualifies: - Type 2 diabetes diagnosis (ICD-10 code in your chart) - Commercial insurance (not Medicare/Medicaid) - Ozempic on your plan's formulary (much more common than Wegovy) - BMI is NOT a requirement here — it's a T2D drug
Why this is relevant for Wegovy seekers: Many patients have prediabetes or borderline T2D that hasn't been formally diagnosed. If your A1C is 5.7-6.4 (prediabetes) or 6.5+ (T2D undiagnosed), getting a formal diagnosis from your PCP unlocks the Ozempic savings path. The molecule is the same as Wegovy — semaglutide — and weight loss is a documented side effect of Ozempic even at the lower 2.0mg dose.
The catch: Off-label use for obesity-only patients isn't supported by Novo Nordisk's program. If you don't have an A1C that supports a T2D diagnosis, this path isn't open.
Path 4: NovoCare cash-pay — $249/month direct from Novo Nordisk
In 2024 Novo Nordisk launched NovoCare, a direct-to-consumer cash-pay program. It's the cheapest brand-Wegovy path that doesn't require insurance or a diabetes diagnosis.
What it costs: $249/month flat for all doses (0.25mg through 2.4mg).
Who qualifies: - No insurance requirement - No diagnosis requirement (other than Wegovy's standard BMI ≥30 or ≥27+comorbidity) - Prescription from any US-licensed prescriber - US resident
How to enroll: Visit novocare.com, complete the eligibility form, get a prescription transmitted from your existing provider OR use NovoCare's affiliated telehealth network.
Why this matters for cash buyers: $249 from Novo Nordisk directly is meaningfully cheaper than retail Wegovy ($1,349) and roughly the same as the mid-tier compounded programs (MyStart at $224, TrimRx at $199, SkinnyRx at $199). The trade-off: NovoCare gives you brand Wegovy in a familiar pen with full Novo Nordisk supply-chain backing. Compounded programs give you the same molecule for $99-$199 but with the regulatory complexity discussed below.
Path 5: Compounded semaglutide — $99-$249/month
Compounded semaglutide is the same active molecule as Wegovy, prepared by a licensed 503A or 503B compounding pharmacy. Currently legal under "personalized formulation" rules (most pharmacies add B12 or glycine to make the formulation non-identical to brand Wegovy).
The 6 verified programs in June 2026, commission-first:
- TrimRx — $199/month (Editor's Choice). Flat pricing at every dose, LegitScript-listed 503B pharmacy, all 50 states, 5-7 day shipping.
- Yucca Health — $146/month on 6-month plan. Cheapest credentialed program; Klarna/Affirm financing.
- MyStart Health — $224/month with code SELFLOVE25. Unlimited clinician access, labs included.
- MEDVi — $179 first month, $299 refills. Lowest first-month entry point for testing.
- Embody — $99/month. Cheapest legit compounded GLP-1; HSA/FSA eligible; oral gum option.
- SkinnyRx — $199/month. No commitment, flat pricing, multi-format delivery options.
For the full pricing matrix and what to look for in a legitimate compounding pharmacy, see our cheapest compounded semaglutide ranking. For step-by-step instructions on switching from brand Wegovy to compounded, see our switching guide.
Path 6: Oral Foundayo (orforglipron) — $149/month
Foundayo (orforglipron) is Eli Lilly's oral GLP-1 pill, FDA-approved April 1, 2026. It's the first GLP-1 that doesn't require injection — a once-daily oral tablet.
What it costs: $149/month through Lilly's launch pricing program.
Why this is a Wegovy alternative: Foundayo's clinical trials showed ~15% body weight loss at 6 months, comparable to Wegovy at 2.4mg. The mechanism is different (orforglipron is a small-molecule GLP-1 agonist, not a peptide like semaglutide), but the clinical outcome is in the same range.
The catch: Foundayo is a fundamentally different molecule than Wegovy. If you've been on Wegovy for months and tolerate it, switching to Foundayo restarts the tolerability adjustment (different side effect profile). If you're starting fresh and don't want injections, Foundayo is an attractive option.
For the full Foundayo launch breakdown see our Foundayo $149/month launch post.
Path 7: Brand Wegovy retail — $1,349/month
The sticker price. Almost nobody actually pays this. If you're paying $1,349, you should immediately: 1. Check whether your plan covers Wegovy (Path 1) 2. Apply for the Wegovy Savings Card (Path 1) 3. Check if you have an undiagnosed T2D (Path 3) 4. Look at NovoCare $249/month (Path 4) 5. Look at compounded semaglutide $99-$249/month (Path 5)
The only people who legitimately pay $1,349 are patients whose plan won't cover Wegovy, who don't have T2D, who haven't applied to NovoCare, and who object to compounded medications. That's a small group — and even within it, NovoCare and the Savings Card paths usually apply.
Decision matrix: which path fits your situation
If you have commercial insurance + Wegovy on formulary: Wegovy Savings Card at $25/month. (Path 1)
If you have commercial insurance + Type 2 diabetes: Ozempic Savings Card at $25/month. (Path 3)
If you're 60+ on Medicare Part D with BMI ≥30: Wait 24 days for the July 1 Medicare bridge at $50/month. (Path 2)
If you're cash-pay (no insurance or Wegovy excluded) and want brand Wegovy: NovoCare at $249/month. (Path 4)
If you're cash-pay and willing to use compounded (same molecule): Embody at $99/month for the cheapest legit option, TrimRx at $199/month for the cleanest experience (Editor's Choice). (Path 5)
If you don't want injections at all: Foundayo (orforglipron) at $149/month. (Path 6)
What the price war means for Wegovy patients
Wegovy retail dropped from $1,349 to $249 (via NovoCare) in about 18 months. Compounded competition pushed Novo Nordisk to compete on cash-pay pricing for the first time in the brand's history. As of June 2026, the floor is $25 (insured) and $99 (compounded).
If FDA closes the compounded personalized-formulation loophole in late 2026 or 2027, NovoCare's $249 becomes the de facto cash-pay floor for brand Wegovy. Whether you commit to compounded today or wait for the regulatory dust to settle depends on your time horizon: compounded saves $150-$200/month over NovoCare, but adds regulatory risk.
For the broader pricing context across all major GLP-1s, see our GLP-1 price war breakdown.
FAQ
Will my Wegovy Savings Card work at any pharmacy? Most major pharmacies (CVS, Walgreens, Walmart, Costco, mail-order). Check the savings card terms for excluded pharmacies.
Can I use the Wegovy Savings Card AND the NovoCare cash-pay program? No — they're alternative paths. NovoCare is for patients without Wegovy insurance coverage. The Savings Card requires Wegovy coverage.
Does the Medicare Bridge cover compounded semaglutide too? No. The bridge specifically covers brand Wegovy (and brand Zepbound). Compounded medications aren't covered by Medicare.
Is compounded semaglutide really the same as Wegovy? The active ingredient (semaglutide) is the same molecule. The legal status (compounded vs. FDA-approved brand), inactive ingredients (most compounders add B12 or glycine), and dispensing format (multi-dose vial vs. pre-filled pen) differ. Clinical effects at equivalent doses are equivalent.
What if I'm already on Wegovy and want to switch to compounded mid-cycle? Same active molecule, 1:1 mg dose conversion, no titration restart needed. See our switching guide for the step-by-step protocol.
How long does NovoCare take to ship? 3-7 business days after prescription approval. NovoCare uses brand Wegovy pens with Novo Nordisk supply chain — faster and more predictable than most compounded programs.
For the full provider grid see our cheapest GLP-1 programs page. For Zepbound's parallel pricing breakdown see our Zepbound cheaper paths post. For the long-term cardiovascular case for staying on Wegovy or any GLP-1, see our Ozempic long-term safety analysis.